Author:
Zhang Peng,Liu Binbin,Chen Xiang,Wang Bin,Dai Cuilian,Wang Yan
Abstract
Growing evidence indicates that severe tricuspid regurgitation (TR) is independently associated with adverse clinical outcomes. The prognostic benefit of isolated TR surgery remains unclear, and medical therapy for decompensated right heart failure alone cannot delay disease progression. TR assessment and management have substantially evolved in recent years. Currently, minimally invasive catheter-based techniques have emerged as a feasible and effective option for TR treatment in high-risk surgical patients. Transcatheter tricuspid valve edge-to-edge repair (T-TEER) has been proposed and applied as an interventional treatment for TR, and has yielded promising preliminary results. This review provides an overview of the current state of T-TEER.
Reference97 articles.
1. Prevalence and severity of Doppler-detected valvular regurgitation and estimation of right-sided cardiac pressures in patients with normal two-dimensional echocardiograms;CJ Lavie;Chest,1993
2. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study);JP Singh;Am J Cardiol,1999
3. Tricuspid regurgitation diagnosis and treatment;M Arsalan;Eur Heart J,2017
4. Burden of tricuspid regurgitation in patients diagnosed in the community setting;Y Topilsky;JACC Cardiovasc Imaging,2019
5. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;CM Otto;Circulation,2021